

Hyphens Pharma launches treatment for Atopic dermatitis (Eczema) expanding its Ceradan® series

19 September 2024 | News

In collaboration with Singapore's A*STAR, Hyphens formulated patented active pH control technology designed specifically for hand eczema esp. among healthcare workers



Hyphens Pharma International Limited, Singapore's leading specialty pharmaceutical and consumer healthcare group, launched Ceradan® Advanced Hand Balm, the latest addition to its Ceradan® line for atopic dermatitis, commonly known as eczema. Ceradan® Advanced Hand Balm, is the first and only hand balm with patented active pH control technology, specifically designed for hand eczema.

A*STAR formulated the Advanced Hand Balm and conducted stability tests to ensure it met quality standards for broader application.

Atopic dermatitis (AD) or commonly known as eczema, is a chronic inflammatory skin condition that affects people of all ages. Hand eczema, characterized by elevated skin pH and a compromised skin barrier, leaves hands susceptible to inflammation caused by external irritants. The issue is particularly prevalent among healthcare workers.

A patented active pH control technology addresses the key challenges of hand eczema by sustainably lowering the skin pH. Skin pH is essential for maintaining skin barrier homeostasis, antimicrobial defense, and controlling inflammation and itch⁴ in hand eczema.

"The launch of the Ceradan® Advanced Hand Balm marks a significant milestone in our mission to provide effective, science-backed solutions for skin health. Recognizing the unique needs of healthcare professionals, it offers targeted relief and lasting protection for hand eczema, empowering them to gain control over their symptoms and regain a better quality of life." said Lim See Wah, Executive Chairman and CEO of Hyphens Pharma.

"Our research partnership with Hyphens Pharma showcases A*STAR's commitment to supporting enterprise growth in Singapore's innovation-driven economy. Through translational research collaborations and intellectual property licensing, we work closely with industry partners to turn scientific advancements into innovative products, solutions and services, driving economic impact for Singapore." said Mr Lim Li-Wei, Executive Director of Innovation & Enterprise, A*STAR.

With Singapore as the regional headquarters, Hyphens Pharma International Limited and its subsidiaries (the Group) has a direct presence in South East Asian countries such as Vietnam, Malaysia, Indonesia and the Philippines.

*Image Caption: (L to R): Dr Ng Wai Kiong, Acting Executive Director, A*STAR Institute of Sustainability for Chemicals, Energy, and Environment (ISCE2); Dr Yew Yik Weng, Senior Consultant Dermatologist and Head of Eczema Clinic, National Skin Centre (NSC); Lim See Wah, Executive Chairman and CEO, Hyphens Pharma; Prof Rachel Watson, Executive Director, A*STAR Skin Research Labs (A*SRL) & Skin Research Institute of Singapore (SRIS)*